I think the biggest message I can offer is a message of hope that the things that people are out there suffering with that seems so impossible to overcome, there are new tools being developed that hopefully will become available widely.

In the case with MDMA, hopefully this year and with silicibin next year on the federal level, it's really devastating to be dealing

with a chronic illness of any kind that you in good faith try everything there is to try and

you still don't get much return for your investment in

the effort and I want people to know that these things are not for everybody

they're not a panacea but there's an incredible opportunity here.

These tools are very powerful and they're not to be played around with lightly, but they have

incredible potential.

So that's where the art of the practice comes in is to try

to discern like what does this person really need?

So these days you're probably seeing more and more headlines in the media about the potential of psychedelic assisted treatments.

Silasibin from quote magic mushrooms MDMA and ketamine being explored as

novel therapies for mental health conditions like depression, PTSD, and anxiety.

We have had a number of guests on to talk about various aspects from the research to the

underground of psychedelics.

But beyond the initial entry, I have become deeply curious.

How much do we really understand about what these substances truly are?

How they work therapeutically, and the real world impacts concerns and

applications for the future of mental health care, which is why I am so excited to share

this frank science-based and practice-based conversation

about this kind of nebulous world of psychedelics. My guest today is Dr.

Will Van der Vandervier. Will is a psychiatrist, researcher, and educator, and co-founder of the Integrative

...